RARS1 inhibits ENO1 ubiquitination and degradation to protect against ferroptosis in hepatocellular carcinoma
AR-DEG-based subtyping reveals distinct LIHC immune profiles. RARS1 promotes LIHC progression through oncogenic signaling and immune modulation, serving as a promising prognostic biomarker and therapeutic target. Targeting RARS1 with agents like AH.6809 may offer novel treatment strategies for LIHC.
Authors
- Di Cui (ORCID: https://orcid.org/0000-0003-2874-6480)
- Jiangtao Yu (ORCID: https://orcid.org/0000-0003-3233-3312)
- Shaolei Zang
- Jian Ma (ORCID: https://orcid.org/0000-0001-9794-4689)
- Lichang Chen (ORCID: https://orcid.org/0000-0003-1173-7131)
Institutions
- Fuyang Normal University (CN)
- Fuyang City People's Hospital (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1686597
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00